The study included data from nearly 17 million adults who received treatment from 2005 to 2011. Researchers compared the stroke rates of patients with atrial fibrillation and those without it.
After two years, TAVR was still linked to a reduction in the study’s primary endpoint, but it was also associated with a greater risk of valve thrombosis.